

#9
107
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-136)

In re the Application of:

Muggetti, et al.

Serial No. 10/070,430

Filed: March 18, 2002

For: Formulations for Parenteral Use of
Estramustine Phosphate with Improved
Pharmacological Properties

Examiner: Khare, D.

Group Art Unit: 1623

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to the duty of disclosure provided by 35 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of the references are enclosed. Copies are also listed in the PTO-1449 form enclosed herewith. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing from the present application. A fee of one hundred eighty dollars (\$180) is enclosed.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is indented as to the relative importance of any portion of the references.

09/26/2003 JBALINAN 00000105 10070430

01 FC:1806

180.00 OP

This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. sections 102 or 103.

CITED REFERENCES


U.S. Patents

	<u>Document Number</u>	<u>Name</u>	<u>Date</u>
1.	4,115,414	Kristensson et al	09/19/78
2.	4,971,802	Tarcsay et al.	10/20/90
3.	5,744,460	Muller et al.	04/28/98

Respectfully submitted,

Date: September 22, 2003

by:



Enrique Perez
Reg. No. 43,853